The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kadyraliev Zh.K.

N.E. Bauman’s City Clinical Hospital #29, Moscow, Russia

Atakanova A.N.

N.E. Bauman’s City Clinical Hospital #29, Moscow, Russia

Experience of sacubitril/valsartan (Uperio) in heart failure and chronic renal disease

Authors:

Kadyraliev Zh.K., Atakanova A.N.

More about the authors

Read: 60390 times


To cite this article:

Kadyraliev ZhK, Atakanova AN. Experience of sacubitril/valsartan (Uperio) in heart failure and chronic renal disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2019;12(5):481‑484. (In Russ.)
https://doi.org/10.17116/kardio201912051481

Recommended articles:
Transapical myectomy in a child with hype­rtrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):357-362
Opti­mal cardioplegia for coro­nary artery bypass grafting in patients with heart failure: a randomized study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):405-411
Cardiogenic deme­ntia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):43-49

References:

  1. Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44:913-918.
  2. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond). 1996;91:283-291.
  3. Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol. 2001;52:159-164.
  4. Maric C, Zheng W, Walther T. Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol. 2006;103:149-156.
  5. Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004;99:76-82.
  6. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol. 1998;31:116-125.
  7. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol. 1999;34:782-790.
  8. Klinicheskie rekomendatsii OSSN—RKO—RNMOT. Serdechnaya nedostatochnost': khronicheskaya (KhSN) i ostraya dekompensirovannaya (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiya. 2018; 58(6).
  9. Kevin Damman, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC: Heart Failure. 2018;6:489-498.
  10. Voors AA, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J heart Fail. 2015;17:510-517.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.